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Background: IKK can promote the ability of p52 to transactivate gene expression in a manner requiring p65.
Results:p52 is induced byTLR3 activation and regulates Sp1 transcription. Sp1 promotes the transcription of IL-15. Both events
require the presence of IKK and p52.
Conclusion: p52 is a target for IKK in antiviral immunity.
Significance: This study reports a role for NFB2 in the induction of antiviral gene expression.
In this study we describe a previously unreported function for
NFB2, anNFB family transcription factor, in antiviral immu-
nity. NFB2 is induced in response to poly(I:C), a mimic of viral
dsRNA. Poly(I:C), acting via TLR3, induces p52-dependent
transactivation of a reporter gene in a manner that requires the
kinase activity of IB kinase  (IKK) and the transactivating
potential of RelA/p65. We identify a novel NFB2 binding site
in the promoter of the transcription factor Sp1 that is required
for Sp1 gene transcription activated by poly(I:C). We show that
Sp1 is required for IL-15 induction by both poly(I:C) and respi-
ratory syncytial virus, a response that also requires NFB2 and
IKK. Our study identifies NFB2 as a target for IKK in antivi-
ral immunity and describes, for the first time, a role for NFB2
in the regulation of gene expression in response to viral
infection.
NFB2 (p100/p52), is a member of the NFB family of tran-
scription factors that comprises fivemammalianmembers: Rel/
c-Rel, RelA/p65, RelB, NFB1 (p50 and its precursor p105), and
NFB2 (p52 and its precursor p100). These proteins exist in
various homo- and heterodimeric complexes and controlmany
biological processes, particularly in inflammation and immu-
nity (1). There are two distinct NFB activation pathways,
termed the canonical and the alternative pathways. The canon-
ical pathway is the better characterized NFB pathway. It is
activated by innate immune receptors, inflammatory cytokines,
and stress pathways and leads to the phosphorylation of the
inhibitory subunit IB by IKK3 and IKK, leading to its deg-
radation. The subsequent release and nuclear translocation of
the p50/p65 dimer leads to the induction of a wide range of
immune and inflammatory genes (1). The alternative pathway
involves NFB2. Known activators of this pathway are CD40,
B-cell activating factor (BAFF) receptor, and lymphotoxin-
(LT-) receptor. Activation of this pathway involves NFB-in-
ducing kinase. NFB-inducing kinase activates IKK, which
phosphorylates p100, causing p100 to be partially processed to
produce the active p52 subunit. Typically, p52 is described as
part of a heterodimer with RelB. This complex is essential for
the role of NFB2 in humoral immunity and secondary lymph-
oid organogenesis.
A third IKK, termed IKK, has been described. IKK is acti-
vated downstream of the dsRNA receptors TLR3, RIG-I, and
MDA5 and by TLR4 and IFN- (2, 3) and, in turn, activates the
transcription factors IRF3, IRF7, STAT1, and p65. IKK has
also been shown to be activated by respiratory syncytial virus
(RSV) and influenza B virus (3, 4).
We identified p52 as a binding partner for IKK in a yeast-
two-hybrid screen and subsequently determined that overex-
pression of IKK could promote the transactivating potential of
p52 (5). However, the functional importance of this interaction
remains elusive. Here we report the uncovering of a signaling
pathway activated byTLR3, or RSV, that involves IKK, NFB2,
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and p65. We identify a conserved binding site for p52 on the
Sp1 promoter and confirm IL-15, an antiviral cytokine, as a
target for Sp1 on this pathway. Our study provides a previously
undescribed function for both NFB2 and Sp1 in antiviral
immunity.
EXPERIMENTAL PROCEDURES
Reagents and Plasmids—LPS, (Alexis Corp.), poly(I:C) and
poly(A:U) (Invivogen) were used. The antibodies used were
p100/p52 (Cell Signaling Technology, catalog no. 4882), -ac-
tin (Sigma-Aldrich, catalog no. A1978), and Sp1 (Millipore, cat-
alog no. 07-645). Oligonucleotides were from Eurofins, and
TaqMan probes were from Applied Biosystems. FLAG-IKK
and IKK(K38A) were provided by Shizuo Akira (Osaka Uni-
versity, Japan). The TBK1-encoding plasmidwas a gift fromDr.
Makato Nakanishi (National Institute for Longevity Sciences,
Japan). HA-p52 was a gift from Neil Perkins (University of
Dundee, Scotland). The Gal-luciferase reporter gene was from
Stratagene. The construction of p52-Gal4 has been described
previously (5). The TRAF1, TRAF3, TRAF6, RIP1, and Nap1
plasmids were gifts from Andrew Bowie (Trinity College Dub-
lin, Ireland). The HA-p65(S536A) plasmid was generated from
the HA-p65 plasmid using the QuikChange XL site-directed
mutagenesis kit (Stratagene).
Cell Culture and Isolation—WT and IKK/ MEFs ob-
tained from Shizuo Akira (Osaka University, Japan), HEK293
cells, and HEK293 cells stably expressing either TLR3
(HEK293-TLR3) (Invivogen) were cultured in DMEM. WT,
NFB2/, and IKK/ (Kate Fitzgerald, University of Mas-
sachusetts) bone marrow was isolated from the tibias and
femurs of C57/Bl6 mice, and the resulting cells were grown in
macrophage colony stimulating factor-conditioned DMEM.
Human peripheral bloodmononuclear cells were isolated from
whole blood using a Ficoll gradient and cultured in RPMI. In all
cases, DMEMandRPMImediumwere supplementedwith 10%
fetal calf serum, 2 mm L-glutamine, and 1% penicillin/strepto-
mycin solution (v/v). Cells were plated at 1 105 cells/ml, and
treated as described before isolation of RNA or lysate for quan-
titative PCR or Western blot analysis, respectively.
Sp1 Promoter Luciferase Construct—For construction of the
Sp1 promoter luciferase reporter gene, we cloned its 5 regula-
tory region of Sp1 from 1303 nt from the translational start
site (ATG) between the NheI and XhoI sites of the reporter
luciferase vector pGL3-enhancer (Promega). Progressive dele-
tion constructs were generated using a common reverse primer
and five different forward primers. The Sp1-specific sequences
for these primers were taken from the EMBL-EBI AF261690
source (in uppercase, see below). For the forward primers, these
specific sequences were preceded by an arbitrary sequence (in
lowercase, see below), including a NheI restriction site (italics).
The reverse primer followed a similar structure but contained a
XhoI restriction site (italics) in the arbitrary sequence. The
numbers indicated after the primer sequences correspond to
the distance in nt from the 5 end of the sequence in uppercase
to the translational start site: forward, 5-tcaagtcaggctagcTT-
GCTTTATGCATAGGCGGT-3 (-1303); forward, 5-tcaagt-
caggctagcCGGATTCTGGTTGGCCGTTGT-3 (-477); for-
ward, 5-tcaagtcaggctagcCTATCAAAGCTTTGCCTATCC-3
(-443); forward, 5-tcaagtcaggctagcGGGAGCCCGCCTGC-
CGGTTG-3 (-415); forward 5-tcaagtcaggctagcTCCTTC-
CAAGCCAATCATCTCC-3 (-388); forward, 5-tcaagtcag-
gctagcGCTCCCGCCCATCTTCACTTC-3 (-365); and re-
verse, 5-cagtgctgcctcgagGCTCAAGGGGGTCCTGTCCGG-3
(-20).
Transfection-based Reporter Gene Assays—Cells were trans-
fectedwithGeneJuice transfection reagent (Novagen,Madison,
WI) with a total amount of 350–400g/well containing 150 ng
of p-55UASGLuc and 50 ng of p52-Gal4 fusion construct
(MEFs) or with a total of 250 ng of DNA containing 100 ng of
p-55UASGLuc or 30 ng of p52-Gal4 (HEK293s). Assays also
contained the plasmidDNAof interest, an empty vector, and 30
ng of Renilla reniformis luciferase construct. For Sp1-promoter-
luciferase assays, HEK293 cells were transfected with a total
amount of 220 ng of DNA/well comprising 80 ng of reporter
construct, the plasmid DNA of interest, 40 ng of R. reniformis
luciferase construct, and an empty vector. Cell extracts were
monitored 24–36 h post-transfection for firefly luciferase
activity following standard protocols with values normalized
for transfection efficiency with R. reniformis luciferase.
RNA Extraction and PCR—MEFs and BMDM or Human
peripheral blood mononuclear cells were set up at 5  105 or
1 106 cells/ml, respectively. Cells were stimulatedwith Poly(I:
C). Total RNAwas extracted using the RNeasy kit (Qiagen). For
mRNA expression analysis, cDNAwas prepared from 20 to 100
ng/ml total RNA using the High-Capacity cDNA archive kit
(Applied Biosystems). Individual mRNAs were monitored with
the following inventoried The AB7900FAST platform (Applied
Biosystems) was used for all PCR, done in triplicate. Changes in
expression were calculated by the change in threshold (CT)
methodwithGapdh as an endogenous control for gene-expres-
sion analysis and were normalized to results obtained with
untreated cells. TaqMan assays were fromApplied Biosystems:
mouse Sp1 assay (Mm00489039_m1), mouse IL-15 assay
(Mm00434210_m1), mouse Gapdh (glyceraldehyde phosphate
dehydrogenase) assay, human Sp1 assay (Hs00916521_m1),
human IL-15 assay (Hs01003713), human Gapdh assay.
siRNA—The following RNA interference duplex was
purchased from Qiagen Hs_NFB2_1 FlexiTube siRNA
SI00300965 and Allstars negative control siRNA (catalog no.
1027281) or Dharmacon ON-TARGET plus siRNA Sp1 (cata-
log no. L-026959). In all cases, 50 nMof siRNAwas used.Human
PBMCs were transfected with siRNA using an Amaxa electro-
porator and a Cell Line Nucleofector Kit V, program V-01
(PBMC). 1  106cells/ml PBMCs were used per point for
nucleofection. Cells were harvested after 72 h and used for fur-
ther analysis.
Immunoblotting—MEFs and BMDMswere seeded at 5 105
cells/ml, HEK293TLR3 cells were seeded at 1  105 cells/ml,
and human peripheral bloodmononuclear cells were set up 1
106 cells/ml 1 day prior to stimulation with 2% FCS. Cells were
stimulated with poly(I:C) and lysed in 1 ml of low-stringency
lysis buffer (50 mM HEPES, 100 mM NaCl, 1 mM EDTA, 10%
glycerol, 0.5% Nonidet P-40, and protease inhibitors). Protein
concentration was measured by Bradford, and equal amounts
of protein were separated by SDS-gel electrophoresis, trans-
A Role for NFB2 in Antiviral Immunity
AUGUST 30, 2013•VOLUME 288•NUMBER 35 JOURNAL OF BIOLOGICAL CHEMISTRY 25067
 at IR
eL (Natl Univ of Ireland, M
aynooth) on September 11, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ferred to a PVDF membrane, incubated with antibody, and
visualized by autoradiography.
Chromatin Immunoprecipitation—Genpathway, Inc. (CA)
carried out an analysis of gene promoters that bound to p52
using samples prepared fromWT and IKK KOMEFs accord-
ing to their instructions. Briefly, MEFs were set up at 5  105
cell/ml. A final volume of 1%, formaldehyde was added directly
to the existing medium and incubated for 15 min. A 1/20 vol-
umeof 2.5M glycinewas then added to each flask and allowed to
set at room temperature for 5 min. Cells were scraped, washed
in PBS, and sent on dry ice to Genpathway, Inc. BMDMs were
set up at 5 105 cell/ml, medium was removed, replaced with
PBS, and fixed by adding a final concentration of 1% formalde-
hyde to each culture dish. Flasks were incubated for 10 min at
room temperature. A 1/20 volume of 2.5 M glycine was then
added to each flask and allowed to set at room temperature for
5 min. The primary antibodies anti-p52 (Abcam, catalog no.
7972), anti-p50 (Millipore, catalog no. 06-886), and anti-p65
(Santa Cruz Biotechnology, catalog no. (F-6) sc-8008) were
determined to give the best ChIP results. Quantitative RT-PCR
was carried out using primers for either the Sp1 promoter or
-actin promoter as indicated. Data are presented as percent of
input.
Affinity Purification with Biotinylated Oligonucleotides—
HEK293 cells were seeded at 1  105 cell/ml and incubated
overnight. Cells were then transfected with either 2 g of
HA-p52 (five plates) or an empty vector control (five plates).
24 h later, cells were lysed in 100l of oligonucleotide buffer (25
mM Tris, 50 mM EDTA, 5% glycerol, 5 mM NaF, Nonidet P-40
1%, 1 mM DTT, 150 mM NaCl, and protease and phosphatase
inhibitors), pooled, and snap-frozen. Samples were then
thawed on ice and diluted with a further 4.5 ml of oligonucleo-
tide buffer withoutNaCl. A 50-l sample of lysatewas kept, and
the remainder was divided into five tubes and incubated for 2 h
with streptavidin-agarose beads conjugated to biotinylated
promoter regions, termed Seq 1–5, as depicted in Fig. 4F.
Lysates were then centrifuged to pellet the beads, which were
washed three times before 50 l of 5 SDS sample buffer was
added to the beads. Samples were then immunoblotted as
indicated.
Viral Infection of BMDMs—RSV long strain (group A) was
obtained from the ATCC and propagated in HEp-2 cells with
serial plaque purifications to reduce defective interfering parti-
cles (6). WT and NFkB2-deficient BMDMs were plated in
6-well (3  106 cells/well) tissue culture plates. Macrophages
were infectedwithRSV (multiplicity of infection 2) or treated
with medium alone and incubated at 37 °C for the indicated
times.
RESULTS
Poly(I:C) Promotes p52-driven Transactivation in an IKK-
and p65-dependentManner—Having previously identified p52
as a protein that interacts with IKK and, furthermore, showing
that IKK promotes transactivation by p52 (5), we wished to
probe the functional relevance of this interaction. Given the
antiviral role of IKK, we chose to test whether the dsRNA
analog P(I:C) could promote p52-mediated transactivation.We
cotransfected HEK293-TLR3 cells with a plasmid encoding
full-length p52 fused to theDNA-binding domain ofGal4 (p52-
Gal4) and aGal4-driven luciferase construct. Fig. 1A shows that
increasing concentrations of the dsRNA analogues P(I:C) and
Poly(A:U) promote p52-driven transactivation. Because P(A:U)
is a dsRNA analog only recognized by TLR3 (7) and P(I:C) and
P(A:U) both promoted p52-driven transactivation to almost
identical levels, the implication is that TLR3, and not the cyto-
solic RIG-1-like receptors, promote p52-driven transactivation.
Having previously identified IKK and p65 in a complex with
p52 (5), we next examined whether IKK and/or p65 mediate
P(I:C)-inducible p52- driven transactivation. P(I:C) failed to
promote p52-driven transactivation in IKK/ MEFs or
p65/MEFs compared with WTMEFs (Fig. 1B). These MEF
strains were responsive to TLR3 ligation, as demonstrated by
comparable levels of P(I:C)-inducible phosphorylation of p38
(not shown).Wenext determinedwhether the kinase activity of
IKK was required for P(I:C)-inducible transactivation by p52.
As shown in Fig. 1C, P(I:C) promoted p52-driven transactiva-
tion to5-fold over the control, whereas a kinase-dead form of
IKK (IKKK38A) inhibited this induction, presumably acting
as a dominant negative inhibitor.
Of the five NFB family members, only c-Rel, p65, and RelB
have transactivating potential (9). p50 and p52 are DNA bind-
ing subunits and are unable to transactivate gene expression on
their own. Becausewe and others have shown that p52 interacts
with p65 (5, 10), we next tested whether p65 was the transacti-
vation partner for p52 downstream of P(I:C). Even small
amounts of p65 could strongly drive p52-dependent transacti-
vation, and this ability of p65 to induce p52 transactivation was
substantially impaired when the serine residue at position 536
in p65 was mutated to an alanine (p65S536A) (Fig. 1D). Phos-
phorylation of p65 at position Ser-536 is known to be very
important for the efficient transactivating potential of p65 in
response to many ligands, and IKK is known to phosphorylate
Ser-536 in response to P(I:C) (8–11). We next investigated
whether p65 could induce p52-dependent transactivation in
IKK/MEFs. As shown in Fig. 1E, p65 induced p52 transac-
tivation in WT MEFs, but this induction was substantially
impaired in IKK/MEFs, indicating that p65 requires IKK
to confer its transactivation potential to p52. IRF3, another
transcription factor with transactivating potential, is activated
downstream of P(I:C) and phosphorylated by IKK (10, 12).
However, IRF3 is unable to mediate transactivation by p52 in
HEK293-TLR3 cells (Fig. 1F). Together, these results imply that
P(I:C) activates IKK, which, in turn, mediates p65 transactiva-
tion of the p52-dependent reporter gene, likely by phosphory-
lating p65 at position Ser-536 (11–14).
We further investigated whether components of the TLR3
signaling pathway could promote p52-driven transactivation.
Fig. 1, G–I demonstrates that TRIF, when overexpressed, can
strongly induce p52-driven transactivation. TRAF3, TRAF6,
RIP1, IKK, and TBK1, all of which are known to be down-
stream of TRIF (13, 14), can promote p52-dependent transac-
tivation in a dose-dependent manner, whereas TRAF1 and the
IKK/TBK1 adaptor NAP1 cannot. To determine whether
TRIF-induced p52 transactivation is mediated by IKK, we
compared the ability of TRIF to drive p52 transactivation in
WT and IKK/ MEFs (Fig. 1J). IKK is required for TRIF-
A Role for NFB2 in Antiviral Immunity
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induced p52 transactivation becauseTRIFwas unable to induce
p52 transactivation in IKK/MEFs (Fig. 1J). All of these data
pointed to p52 as an important target for TLR3 signaling, and
we further confirmed this by demonstrating that expression
levels of both p100 and p52 were induced by P(I:C) in a dose-
dependent manner (Fig. 1K).
FIGURE 1.Poly(I:C) inducesp100andp52expressionandp52-dependent transactivation in an IKK- andp65-dependentmanner.A–J, p52-dependent
transactivation was assayed in all cells using 150 ng of p-55UASGLuc and 50 ng of p52-Gal4 or Gal4-DBD. HEK293-TLR3 cells were stimulated with poly(A:U) or
poly(I:C) 24 h post-transfection or left untreated (Control) and incubated for 6 h (A) or cotransfected with a plasmid encoding IKKKA (C), p65, p65S536A, or
empty vector (EV) (D). B, WT, IKK KO, or p65 KOMEFs were stimulated with P(I:C) 24 h post-transfection or left untreated (control) and incubated for 6 h. E, WT
and IKK KO MEFs were cotransfected with p65 or EV as indicated. F–I, HEK293 cells or wild-type and IKK/ MEFs (J) were cotransfected with plasmid
encoding IRF3 (F); p65 (G); Trif (J); TRAF1, TRAF3, TRAF6, and RIP1 (H); IKK, Nap1, and TBK1 (I) or with empty vector only, as indicated. Luciferase activity was
determined 24–36 h after transfection. Data are the means of three measurements, with error bars representing S.D. K, HEK293-TLR3 cells were treated with
increasing doses of P(I:C) for 24 h, lysed, and probed for p100/p52. Data are representative of three separate experiments.
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p52 Binds to the Promoter of the Sp1 Gene to Activate Its
Transcription—Having shown that p52 is induced and acti-
vated by P(I:C), we next interrogated the gene promoters that
were bound by p52 in response to P(I:C).We carried out a ChIP
analysis to determine genes to which p52 might bind. This was
carried out commercially by Genpathway, Inc., who revealed
that p52 binds to an enhancer sequence in the Sp1 gene pro-
moter in the region shown in Fig. 2A. We next carried out a
ChIP analysis comparing WT and IKK/ BMDMs treated
with P(I:C) for 3 h. As shown in Fig. 2B, there was no difference
between WT and IKK/ cells in the basal binding of p52 to
the Sp1 promoter. However, P(I:C) induced a 5-fold increase in
binding of p52 to the Sp1 promoter in WT BMDMs, and this
was abrogated in IKK/ BMDMs. We also investigated the
binding of the NFB subunit p65 to the Sp1 promoter. p65
binding to the promoter was increased significantly, 2-fold, in
A Role for NFB2 in Antiviral Immunity
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response to P(I:C). Binding of p65 to the TNF promoter was
measured as a positive control for p65 binding (not shown). p52
binding was again evident in the P(I:C)-treated cells (Fig. 2C).
To examine this region further and locate the DNA element
important for the transcriptional regulation of the Sp1 gene by
p52, a series of 5-deletion promoter constructs was generated
by PCR and cloned into the promoterless pGL3 enhancer lucif-
erase reporter vector. The resulting constructs contain 5 flank-
ing regions from 20 to 474, 443, 412, 385, and 362
relative to the translational start codon. HEK293 cells were
transfected with the deletion constructs in conjunction with
increasing amounts of plasmid expressing HA-p52. A 4-fold
increase in activity was induced by cotransfection of pGL3-474
with HA-p52 compared with that of pGL3-474 alone (Fig. 2D).
Deletion to 443 abolished this activity, which was also abol-
ished in all other constructs (not shown). These results demon-
strate that the Sp1 promoter is activated by p52 in the region of
sequence between 443 and 474 nt relative to the start site.
We next employed an oligo pull-down assay to assess whether
P(I:C) could induce the binding of p52 and p65 to this region of
the promoter (443 to 474). This is clearly the case because
P(I:C) specifically induced the binding of both p52 (Fig. 2E,
second panel) and p65 (third panel) but not p100 (first panel) or
p50 (fourth panel) to the oligonucleotide sequence indentified
from the Sp1 luciferase assay. Interestingly, the bound form of
p65 appears to be in a phosphorylated state because we were
also able to weakly detect P-p65S536 in the induced complex
(Fig. 2E, fourth panel).
We further defined the p52 binding site using this assay.
Overexpressed HA-p52 binds to the oligonucleotide consisting
of the sequence from434 to472 (Fig. 2F, Seq 1, lane 2) and
also to the sequences from443 to472 (Seq 2, lane 4), from
452 to 472 (Seq 3, lane 6), and from 434 to 462 (Seq 4,
lane 8). However, HA-p52 does not bind to the oligonucleotide
consisting of the sequence from434 to452 (Seq 5, lane 10)
(Fig. 2F). Sequence 5 differs from the sequences 1–4 in that it
lacks the sequence GGCCGTTGTT. Interestingly, this area in
the promoter of Sp1 is conserved among species (Fig. 2G). This
identifies, for the first time, GGCCGTTGTT as a binding site
for p52.
Having demonstrated that p52 binds to the Sp1 promoter, we
next tested the functional consequences of this response. As
shown in Fig. 2H, P(I:C) induced the expression of Sp1mRNA
in WT BMDMs, whereas this effect was not observed in either
IKK/ or NFB2/ BMDMs. To determine whether this
effect could be seen in human cells, siRNA directed against
NFB2 or a non-targeting control were transfected into
PBMCs, and Sp1 induction was measured. P(I:C) induced Sp1
expression in control cells. This induction was lost in NFB2
knockdown cells (Fig. 2I).
Sp1, IKK, and NFB2 Regulate IL-15 Gene Transcription—
Wenext determined target genes for Sp1 thatmight be relevant
to the antiviral response. The promoter of IL-15, a proinflam-
matory, antiviral cytokine, was strongly predicted to be regu-
lated by Sp1. IL-15 is known to be induced by P(I:C) and by viral
infection (16, 17).Wehypothesized that a P(I:C)-inducible gene
regulated by Sp1 should not be induced in either IKK or
NFB2 knockout cells. To validate IL-15 as a Sp1 target gene,
human PBMCs were transfected with siRNA directed against
Sp1 or a non-targeting control, and IL-15 induction was meas-
ured. P(I:C) caused an increase in the level of IL-15mRNA over
time thatwas lost in cells deficient in Sp1 (Fig. 3A). Importantly,
Sp1 knockdown did not reduce the ability of the PBMCs to
induce IL-6 (not shown) or RANTES (regulated on activation,
normal T cell expressed and secreted), which was, in fact,
increased upon Sp1 knockdown (Fig. 3B). These are Sp1-inde-
pendent, P(I:C)-inducible genes indicating specificity in the
IL-15 observation. This effect was confirmed pharmacologi-
cally in PBMCs pretreated with 1 M mithramycin A (MMA),
an Sp1 inhibitor. P(I:C) caused an5-fold increase in the level
of IL-15mRNAover basal levels after 8 h. This effect was inhib-
ited by pretreatment with mithramycin A (Fig. 3C).
Following this, wemeasured the IL-15 transcript in response
to P(I:C) inWT,NFB2/, and IKK/BMDMs. IL-15 tran-
script levels increased 60-fold in WT BMDMs after 8 h of
poly(I:C) treatment, whereas a marked inhibition of this
response was observed in both NFB2/ and IKK/
BMDMs (Fig. 3D). This dependence of P(I:C)-induced IL-15
levels on NFB2 was confirmed in human PBMC, whereas no
increase was observed in PBMCs transfected with siRNA tar-
FIGURE 2. Poly(I:C) induces p52 and p65 to bind a previously undescribed site in the Sp1 promoter to drive transcription in an IKK-, p65-, and
NFB2-dependentmanner.A, a partial sequence of the Sp1promoter region474 nt to362 nt 5 from the start codon. The primers used for the ChIP assay
are underlined. B, WT and IKK KO BMDMswere treatedwith P(I:C) for 3 h or left untreated, after which a ChIP assaywas performed using an anti-p52 antibody.
Primers specific for promoters of Sp1 or-actinwere designed, and binding events of p52weremeasured as percent of input. C, WT BMDMswere treatedwith
P(I:C) for 0, 3, and 6 h, after which a ChIP assay was performed using antibodies against HA (control), p65, or p52. Binding events weremeasured as percent of
input. Data are themeans of threemeasurements, with error bars representing S.D. Statistical analysis was carried out using Student’s t test. *, p 0.05; **, p
0.001; ***,p0.0001. Values are representative of three separate experiments.D, Sp1promoter truncationswere cloned into apGL3 luciferase reporter vector,
and Sp1 promoter activity was assayed in HEK293 cells transfectedwith 80 ng of pGL3 vector containing Sp1 promoter truncations474 and443 nt 5 from
the start site, respectively, or with pGL3 vector alone. Cells were cotransfected with a plasmid encoding HA-p52. Luciferase activity was determined 24 h after
transfection and is represented as fold increase in luciferase over each individual pGL3-Sp1 promoter construct or empty vector control. Data are themeans of
three measurements, with error bars representing S.D. Values are representative of three independent experiments. E, HEK293-TLR3 cells were treated with
P(I:C) for 0 and 3 h, lysed, and an oligo pull-down (OPD) assaywas carried outwith the472 to434 oligo sequence. Sampleswere probed for p100, p52, p65,
P-p65S536, andp50. F, anOPDassaywas carried out inHEK293 cells using the oligonucleotide sequence from472 to434 5 from the Sp1 translational start
codon (Seq 1) and truncations of this nucleotide sequence (Seq 2–5) as shown in the bottom panel. Cells were transfected with a plasmid encoding either
HA-p52 () or empty vector (). 24 h later, cells were lysed, incubated with oligos as indicated, and probed for HA (top panel). OPD assays are representative
of two separate experiments. G, species sequence alignment of the site in the Sp1-promoter. Upstream regions were obtained via biomart taking the flanked
regions 2500base pairs upstream. An alignmentwas createdusingMUSCLE. The alignmentwas viewed, and an imagewas exported via Jalview. The 10 central
base pairs in the alignment are the binding site. The binding site starts364 upstream from the gene start site in the human sequence. H, WT, IKK KO, and
NFB2 KOBMDMs or PBMCs (I) transfectedwith either siRNA targetingNFB2 or a non-targeting control siRNA for 48 hwere stimulatedwith P(I:C) for 0, 4, and
8 h, as indicated. H and I, quantitative RT-PCR analysis of RNA from these cells was carried out with primers specific for Sp1. Expression is normalized to that of
GAPDH and is presented relative to that of untreated controls. Data are the mean of at least three separate experiments with each point assayed in triplicate.
Error bars represent S.D.
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geted against NFB2 (Fig. 3E). These data, therefore, implicate
IKK, NFB2, and Sp1 in the induction of IL-15 by P(I:C).
RSV Infection Fails to Up-regulate Sp1 and IL-15 Transcripts
in Both IKKandNFB2Knockout BMDMs—Finally, we exam-
inedwhether this pathwaywas important for induction of IL-15
by a virus. RSV is recognized by TLR3 during infection (18, 19)
and is a powerful inducer of IL-15 (16). We infected WT,
IKK/, and NFB2/ BMDMs with RSV (multiplicity of
infection 2) for 4, 8, or 24 h and measured Sp1 mRNA levels.
As shown in Fig. 4A, left panel, the Sp1 transcript was induced
10-fold after 4 h of RSV infection in WT BMDMs. Conversely
no induction of Sp1 was observed in IKK/ BMDMs after
RSV infection (Fig. 4A, right panel). Similarly, no Sp1 was
inducible by RSV infection in NFB2/ BMDMs (Fig. 4B). As
shown in Fig. 4C, left panel, IL-15 is induced by RSV in WT
BMDMs. However, this induction of IL-15 is completely abro-
gated in RSV-infected IKK/ BMDMs (Fig. 4C, right panel).
Similarly, RSV-induced IL-15 is abrogated in NFB2/
BMDMs (Fig. 4D, right panel). To determine the specificity of
the effect of NFB2 and IKK on RSV-inducible IL-15, we
measured levels of IFN and IL-12p40, two further RSV-induc-
ible genes, and found that neither NFB2 or IKK deficiency
reduced the levels of these cytokines in response to RSV infec-
tion (Fig. 4,E–H). These results, therefore, indicate that, similar
to P(I:C), RSV infection will trigger a pathway involving NFB2
and activated by IKK, leading to up-regulation of Sp1 and
induction of IL-15, which could be critical for antiviral
immunity.
DISCUSSION
In the NFB field, the majority of studies concerned with
infection and inflammation have centered on the canonical
NFB pathway, whereas NFB2 is better known for its func-
tions in lymphoid organogenesis and humoral immunity (20).
In this study, we present a novel inducer and activator of
NFB2 in the formof Poly(I:C) that acts via TLR3. A few studies
have identified an indirect role forNFB2 in host defense.With
respect to viral immunity, RSV infection has been shown to
induce the release of p65 from p100/p65 complexes (21). How-
ever, the elucidation of genes potentially regulated byNFB2 in
the host response to infection has been unexplored.
Sp1 was identified as a target gene for p52 in response to
poly(I:C) through ChIP analysis. Sp1 is a transcription factor
first identified on the basis of its ability to interact with the
FIGURE 3. IL-15 induction in response to poly(I:C) requires Sp1, IKK, and NFB2. A, B, and E, PBMCs were transfected with siRNA targeting Sp1 (A and B),
NFB2 (E), or a non-targeting control siRNA for 48 h. Cells were then stimulated with P(I:C) for 0, 4, and 8 h as indicated. C, PBMCs were pretreated for 1 h with
1Mmithramycin A (MMA) or left untreated before stimulationwith P(I:C).D, WT, IKK/, and NFB2/ BMDMswere stimulatedwith P(I:C) for 4, 8, and 24 h
or left untreated, as indicated. In each case, RT-PCR analysis of RNA was carried out with primers specific for IL-15 or RANTES, as indicated. Expression is
normalized to that of GAPDH and is presented relative to that of untreated controls. Data are themean of at least three separate experiments with each point
assayed in triplicate, with error bars representing S.D.
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GC-richmotif of simian virus 40 regulatory sequences (22). Sp1
plays a critical role in many diverse cellular events, such as cell
growth (23), differentiation (24), apoptosis (23), angiogenesis
(25), and viral latency (26), by regulating the expression of other
genes. Sp1 was once thought to serve mainly as a constitutive
activator of housekeeping genes. However, growing evidence
indicates that various posttranslationalmodifications can influ-
ence the transcriptional activity and stability of Sp1, making it a
transcription factor responsive to extracellular signals.
Sp1 associates physically and cooperates functionally with
several cellular transcriptional activators and also with several
viral regulatory proteins, including the HIV-1 regulatory pro-
tein Tat (27) and the immediate early gene products of human
cytomegalovirus (28). These associations determine the level of
Sp1-mediated, viral, or host gene transcription (29, 30). Fur-
thermore, Sp1-regulated elements are found in the promoters
of various viruses such as HIV-1 (26), SV40 (22), HSV-1 (31),
HCMV (32), and EBV (33). The fact that recognition elements
of Sp1 are frequently found in the promoters of various viral
genes and, furthermore, that viral regulatory proteins associate
with Sp1 to affect its transactivating potential implies that
viruses have hijacked the host response to infection in the form
of increased Sp1 availability to their own advantage. This indi-
cates that Sp1 induction upon viral infection is probably a com-
mon event during host defense. However, although there is an
abundance of circumstantial evidence indicating a role for Sp1
in host defense against viral infection, only one study has dem-
onstrated a functional role for Sp1 in the antiviral response in
the skin to Vaccinia virus through its regulation of OAS2
expression (34). Therefore, we considered Sp1 a valid target for
further investigation.
The identification of sequences to which NFB dimers bind
and effect gene expression in a dimer-specific manner is under
intense investigation. Active NFB dimers bind to specific
DNA sites in the promoters of target genes that are collectively
known as B sites (35). The classical B sites follow the
5-GGGRNWYYCC-3 consensus (r purine, Y pyrimidine,
W  A or T, and n  any nucleotide). However, it has been
reported that the p52/RelB heterodimer binds to and activates a
unique class of B site with the consensus 5-RGGAGAY-
TTR-3 (r A or G and Y C or T). This consensus sequence
is present in the promoters of chemokines involved in lymphoid
development and the maintenance of the splenic architecture
(36). With increasing numbers of NFB-regulated DNA target
FIGURE 4. RSV infection induces both Sp1 and IL-15 in an IKK- and NFB2-dependentmanner.WT, IKK /, and NFB2/ BMDMswere infected with
theRSV long strain (groupA) (multiplicity of infection2) or treatedwithmedium for 2, 4, 8, or 24h. Cellswere lysed, andRNAwasextracted for RT-PCRanalysis
with primers specific for Sp1 (A and B), IL-15 (C and D), IFN (E and F), or IL-12p40 (G and H). Expression was normalized to that of GAPDH and is presented
relative to that of untreated controls. Data are representative of three separate experiments, with each point assayed in triplicate, with error bars representing
S.D.
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sites being discovered, the diversity of these B-sequences is
becomingmore apparent, with even the stringency of the GGG
and CC core sequences called into question (37). Our study has
identified a previously undescribed B site, 5-GGCCGTT-
GTT-3, targeted by p52/p65 in the promoter of the Sp1 gene in
the region between 474 and 443 nt from the translational
start site.
Functionally, we have demonstrated that Sp1 mRNA and
protein levels increase upon P(I:C) treatment and that this
increase is not observed in cells lacking either IKK, p65, or
NFB2. We chose IL-15 as a possible candidate when consid-
ering which target genes might be regulated by Sp1. The role of
IL-15 in host defense against viral infections is well docu-
mented, and it is known to be induced in response to numerous
viruses, including RSV (16, 38). IL-15 is a potently proinflam-
matory cytokine with a diverse range of immunoregulatory
functions (39). The IL-15 gene promoter is also predicted to
have two Sp1 sites (40). We confirmed that IL-15 gene expres-
sion requires the presence of active Sp1 in PBMCs in response
to P(I:C) and that its induction requires both IKK and NFB2.
Finally, we examined the role of IKK and NFB2 in a viral
infection model. RSV is a major human respiratory pathogen
and the leading cause of lower respiratory tract infection in
infants worldwide (19). RSV is a single-stranded RNA virus.
However, it makes dsRNA during its replication cycle, and it
has been reported that TLR3 mediates inflammatory cytokine
and chemokine production in response to RSV infection (19,
41).
Knocking out IKK alone completely abrogates any Sp1 or
IL-15 gene expression in response to RSV. It is known that IKK
phosphorylates both IRF3 and p65 in response to RSV to
increase the transactivation potential of these transcription fac-
tors (4, 42). Because the IL-15 promoter has also been shown to
have a virus-inducible region encompassing an interferon reg-
ulatory factor element and a consensus NFB motif (43), the
lack of IL-15 gene expression in response to RSV in IKK-defi-
cient BMDMs could conceivably be due to the insufficient
transactivation of p65 and IRF3. However, we believe this is
unlikely because other kinases can act in place of IKK in this
role, most notably TBK1 and IKK (8, 12). In addition, we
observed that BMDMs that lack NFB2 also fail to up-regulate
IL-15 gene expression in response to either P(I:C) or RSV, sug-
gesting that IKK acts upstream of NFB2 in our system. The
mechanism of P(I:C)- and RSV-induced IL-15 expression is
likely due to the ligation of TLR3, which both activates IKK
and induces p52. p52 then binds the promoter of Sp1 with p65,
inducing its expression, and Sp1 then binds the promoter of
IL-15, up-regulating its expression.Wewere unable to test RSV
in vivo in NFB2/ mice because they are severely immuno-
compromised because of defective lymphoid organogenesis
(20, 44).
The number of genes regulated by IKK in a non-redundant
manner are very few (3), so it is of interest that we report two
new genes to add to this list, i.e. Sp1 and IL-15. Similarly, the
number of genes known to be regulated by NFB2 is small in
number and relate only to lymphoid organogenesis, humoral
immunity, and DNA damage (36, 45, 46). Considering the
abundance of functions of IL-15 (41), we therefore present a
role for NFB2 as a key regulator of antiviral immunity. Fur-
thermore, TLR3 signaling is activated by viral, bacterial, and
parasite-derived dsRNAor by host-derivedmRNA (47). There-
fore, it is conceivable that NFB2 alone or in conjunction with
Sp1will be found to play a role in host defense against a broader
range of infectious agents and also in autoimmunity.
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